ROCKVILLE, Md.--(BUSINESS WIRE)--Sia Anagnostou, Senior Director of Corporate Development at Immunomic Therapeutics, Inc., will participate in a BioPharma Dealmakers webcast, sponsored in part by Immunomic Therapeutics, Inc. The webcast, part of Nature Biotechnology’s BioPharma Dealmakers series, is scheduled for 11 am EDT on June 13th and will feature three other companies innovating cancer immunotherapy.
This webcast will showcase a range of cancer immunotherapy innovations and explain how they are advancing progress within immuno-oncology. Technologies covered within the webcast will include: LAMP-Vax, Immunomic’s unique immunotherapy platform creating nucleic acid-based vaccines; Bioclonics, differentiated bispecific antibody therapeutics; targeted radioimmunotherapies, antibodies delivering radioisotopes and a precision engineering platform IsoCode for predictive cell response.
The webcast will conclude with a live roundtable discussion and question and answer session to allow viewers to dialogue with the speakers.
Sia Anagnostou is responsible for several core areas including business and corporate development, alliance development and portfolio management at Immunomic Therapeutics, Inc. Anagnostou previously worked with Theranostics Health, a company focused on cancer proteomic molecular diagnostics.
Other webcast participants include:
- Prof. Ton Logtenberg, Founder and Chief Executive Officer, Merus N.V.
- Sean Mackay, Co-Founder, Chief Executive Officer and Director, IsoPlexis
- Dr. Mark Berger, Chief Medical Officer, Actinium Pharmaceuticals, Inc.
- Moderator: Raveena Bhambra, Editor of BioPharma Dealmakers. Raveena has worked in the biopharma industry for over 10 years specifically in the areas of deal making, partnering and licensing.
About the Webcast
BioPharma Dealmakers webcasts are dedicated to small and large companies ready for commercial partnerships. Read the quarterly BioPharma Dealmakers supplement in Nature Biotechnology and Nature Reviews Drug Discovery.
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. On the heels of two landmark deals in 2015, including an exclusive worldwide license with Astellas Pharma Inc. to explore the use of LAMP-Vax for use in the prevention and treatment of allergic diseases which resulted in over $350M in licensing revenue that year, the company has now focused on the application of LAMP technology in oncology. For information about ITI and LAMP technology, visit www.immunomix.com.
ITI’s investigational LAMP-Vax platform is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in humans. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put LAMP-Vax technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. LAMP is currently being employed in Phase II clinical trials as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of LAMP in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for LAMP-Vax therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.